Biofrontera announced FDA approval of Ameluz for superficial basal cell carcinoma, expanding the therapy's market reach. This approval establishes it as the only FDA-approved photodynamic therapy for skin cancer treatment in the U.S.
Biofrontera announced FDA approval of Ameluz for superficial basal cell carcinoma, expanding the therapy's market reach. This approval establishes it as the only FDA-approved photodynamic therapy for skin cancer treatment in the U.S.